Bi/multi-Specific Antibody can recognize and bind to two or more different antigens or epitopes. Through our bi/multi-Specific platform, molecules with unique MOA or synergistic effects can be obtained through the combination of different targets.
Our CD3 Engager has a variety of designs for different targets, including symmetric/asymmetric, anti-CD3 activity and anti-TAA target activity fine-tuning, different valency and spatial structure, to achieve a balance between efficacy and safety.
Simultaneously targeting two different targets may exert bifunctional effect or reduce the toxicity to achieve better clinical results.
This type of antibody is directed against two different epitopes of the same target to obtain a molecule with higher avidity and unique MOA.